ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Syringic acid attenuates chlorpyrifos-induced redox imbalance, mitochondrial depolarization, and apoptosis-related transcriptional changes in HepG2 cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlorpyrifos (CPF) is an organophosphate pesticide associated with hepatocellular toxicity, oxidative stress, and mitochondrial dysfunction. Syringic acid (SA) is a naturally occurring phenolic acid known for its antioxidant and cytoprotective properties. This study evaluated whether SA attenuates CPF-induced injury in HepG2 cells by assessing cytotoxicity, oxidative stress parameters, mitochondrial membrane potential, cell-cycle distribution, and mRNA expression of genes related to antioxidant defense, inflammation, and apoptosis. CPF exposure reduced MTT-derived metabolic activity and increased membrane damage, intracellular oxidant-associated DCF fluorescence, total oxidant status, and malondialdehyde, while decreasing total antioxidant capacity, superoxide dismutase, and glutathione peroxidase activities. CPF also increased mitochondrial depolarization and altered antioxidant-, inflammation-, and apoptosis-related mRNA expression. Co-treatment of SA with CPF attenuated oxidative stress, improved antioxidant-related biochemical parameters, reduced mitochondrial depolarization, and partially normalized these transcriptional changes. These findings indicate that SA attenuates CPF-induced cellular injury in association with improved redox status, preserved mitochondrial membrane potential, and changes in stress-related transcripts.
Indexed as
Identifiers
42789046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.